The device works using a small electrical charge.
The technology, called Tissue Nanotransfection (TNT) uses nanotechnology to turn skin cells into a range of other types of cell that can be used to fix damaged tissues. "You simply touch the chip to the wounded area, then remove it", said Chandan Sen, director, center for regenerative medicine and cell-based therapies, The Ohio State University Wexner Medical Center.
A small electric current fires DNA into skin cells to convert them into natural cell building blocks which helps to fix the damaged areas such as arteries and even organs like the heart. The RNA or DNA is injected into those channels where it takes root and starts to reprogram the cells.
"By using our novel nanochip technology, injured or compromised organs can be replaced", said study co-author Dr Chandan Sen in a statement. These included using the device to act upon badly injured legs that lacked blood flow.
It takes just a fraction of a second.
Researchers from the Ohio State University in the USA developed a new technology called Tissue Nanotransfection (TNT) and tested it on mice and pigs. One week after the application of TNT, vascular vessels reappeared.
The study, published today in Nature Nanotechnology, was conducted on mice and pigs.
TNT technology has two major components: First is a nanotechnology-based chip created to deliver cargo to adult cells in the live body.
"This is hard to imagine, but it is achievable, successfully working about 98% of the time".
Because it is the body's own cells that are being converted, the immune system does not attack them and so there is no need for immunosuppressant drugs.
Co-lead author Professor James Lee added: "The concept is very simple". Actually, the Researchers managed to grow brain cells on the skin surface of a mouse, harvest them and then inject them into the injured brain of the mouse. "As a matter of fact, we were even surprised how it worked so well".
It does not require any laboratory-based procedures, according to Gallego-Perez, and can be used at the point of care - a doctor's office, say, or an outpatient clinic. In my lab, we have ongoing research trying to understand the mechanism and do even better.
The technology is now waiting for FDA approval, but Sen expects the device to enter human trial within the year.